Article
Infectious Diseases
Michael Ruzicka, Sonja Wurm, Lars Lindner, Martin Dreyling, Michael Von Bergwelt-Baildon, Stefan Boeck, Clemens Giessen-Jung, Valeria Milani, Joachim H. Stemmler, Marion Subklewe, Oliver Weigert, Karsten Spiekermann
Summary: Thrombocytopenia after COVID-19 vaccination should be diagnosed to exclude vaccine-induced immune thrombotic thrombocytopenia (VITT) and, if confirmed, treated according to current ITP guidelines. Re-vaccination of patients seems feasible under close monitoring of blood counts and using a vaccine that differs from the one triggering the initial episode of VA-ITP.
Article
Infectious Diseases
Adelina Raluca Marinescu, Voichita Elena Lazureanu, Virgil Filaret Musta, Narcisa Daniela Nicolescu, Alexandra Mocanu, Talida Georgiana Cut, Camelia Oana Muresan, Cristina Tudoran, Monica Licker, Ruxandra Laza
Summary: COVID-19 infection in children can lead to immune thrombocytopenic purpura (ITP), characterized by low platelet count and bleeding symptoms. Prompt diagnosis and treatment with intravenous immunoglobulin (IVIG) and corticosteroids can lead to platelet count recovery.
INFECTION AND DRUG RESISTANCE
(2022)
Correction
Medicine, General & Internal
Douglas B. Cines, James B. Bussel
Summary: The Covid-19 pandemic led to the rapid development of highly effective vaccines, with over 400 million people vaccinated so far and a remarkably low risk of serious adverse reactions.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Hematology
Ilene Ceil Weitz, Howard Allen Liebman
Summary: Immune thrombocytopenia (ITP) is a disorder characterized by low platelets due to increased clearance and decreased platelet production. The interaction between platelet autoantibodies and the complement system plays an important role in ITP. A recent clinical trial has shown the efficacy of complement inhibitors in refractory ITP patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Beatriz de la Cruz-Benito, Maria I. Rivas-Pollmar, Maria T. Alvarez Roman, Roberto Trelles-Martinez, Monica Martin-Salces, Paula Lazaro-del Campo, Andres Ramirez-Lopez, Sara Garcia-Barcenilla, Tamara Cebanu, Paula Acuna-Butta, Elena Monzon-Manzano, Elena Gonzalez-Zorrilla, Victor Jimenez-Yuste, Nora V. Butta
Summary: Thrombocytosis may occur in patients with chronic ITP following SARS-CoV-2 infection, often requiring treatment adjustments. The response is relatively rapid, possibly due to decreased immune activity during COVID-19.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Virology
Sana Shabbir, Muhammad Hassan Raza, Muhammad Arshad, Muhammad Jawad Khan
Summary: The global population has been significantly impacted by COVID-19, caused by SARS-CoV-2 with no effective treatment options available. Research has shown that patients exhibit active immune responses, potentially leading to issues like cytokine storm syndrome.
ARCHIVES OF VIROLOGY
(2021)
Article
Oncology
Shipra Kaicker, Kirsten Martinko, James B. Bussel
Summary: Recent research has found that COVID-19 vaccines have minimal impact on platelet counts and bleeding in children, adolescents, and young adults with preexisting immune thrombocytopenia (ITP), with only a few cases of transient platelet count decrease reported.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Hematology
C. Schaefers, F. -O. Paulsen, C. Frenzel, K. Weisel, C. Bokemeyer, C. Seidel
Summary: We conducted a retrospective single-center analysis to compare the cases of immune thrombocytopenia (ITP) detected in 2021 with previous years. A significant increase in ITP cases, including those related to COVID-19 vaccines, was observed in 2021 compared to the pre-vaccination years. Further studies globally are necessary to explore this finding.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Laura Mansi, Laurie Spehner, Etienne Daguindau, Kevin Bouiller, Hamadi Almotlak, Ulrich Stein, Adeline Bouard, Stefano Kim, Elodie Klajer, Marine Jary, Guillaume Meynard, Angelique Vienot, Charlee Nardin, Fernando Bazan, Quentin Lepiller, Virginie Westeel, Olivier Adotevi, Christophe Borg, Marie Kroemer
Summary: Cancer patients exposed to SARS-CoV-2 produced a high rate of specific antibodies, but lacked T-cell responses against the virus, indicating a deficiency in protective T-cell immunity. However, their immune memory against common viruses remained intact.
EUROPEAN JOURNAL OF CANCER
(2021)
Editorial Material
Hematology
Kristen M. Sanfilippo, Adam Cuker
Summary: Guillet et al. report in the journal Blood that there are high rates of sustained platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP) following discontinuation of thrombopoietin receptor agonist (TPO-RA) therapy and documented complete response (platelet count > 100 x 10(9)/L).(1)
Article
Medicine, Research & Experimental
Han-Sol Park, Janna R. Shapiro, Ioannis Sitaras, Bezawit A. Woldemeskel, Caroline C. Garliss, Amanda Dziedzic, Jaiprasath Sachithanandham, Anne E. Jedlicka, Christopher A. Caputo, Kimberly E. Rousseau, Manjusha Thakar, San Suwanmanee, Pricila Hauk, Lateef Aliyu, Natalia Majewska, Sushmita Koley, Bela Patel, Patrick Broderick, Giselle Mosnaim, Sonya L. Heath, Emily S. Spivak, Aarthi Shenoy, Evan M. Bloch, Thomas J. Gniadek, Shmuel Shoham, Arturo Casadevall, Daniel Hanley, Andrea L. Cox, Oliver Laeyendecker, Michael J. Betenbaugh, Steven M. Cramer, Heba H. Mostafa, Andrew Pekosz, Joel N. Blankson, Sabra L. Klein, Aaron A. R. Tobian, David Sullivan, Kelly A. Gebo
Summary: Benchmarks for protective immunity from infection or severe disease after SARS-CoV-2 vaccination are still being defined. In this study, the researchers compared different immune responses and viral variants in different groups, including vaccinated individuals and symptomatic patients. The findings showed that neutralizing antibody levels declined over time and were lower against the Alpha variant. Partially and fully vaccinated patients had lower neutralizing antibody levels against the parent virus compared to healthy controls. The study also found that neutralization activity against the Alpha variant was lower in the partially and fully vaccinated infected patients. Parent virus neutralization was identified as a predictive factor for breakthrough infections with the Alpha variant.
Article
Immunology
Po-Wei Liao, Chieh-Lin Jerry Teng, Cheng-Wei Chou
Summary: A case of immune thrombocytopenia induced by chimpanzee adenovirus-vectored vaccine highlighted the rare side effects that can be caused by this type of vaccine, including immune thrombotic thrombocytopenia. This case demonstrated the potential for immune thrombocytopenia without thrombosis, emphasizing the importance of vigilance as global vaccine administrations against coronavirus disease increase.
Article
Pediatrics
Kazuma Shinno, Yoshinori Banno, Isamu Kamimaki
Summary: A pediatric case of severe immune thrombocytopenia (ITP) following a COVID-19 diagnosis is reported. The six-year-old girl experienced symptoms of high fever, sore throat, and headache, as well as gingival hemorrhage and petechiae. Based on mucosal hemorrhage and low platelet count, she was diagnosed with severe ITP and treated with IVIG. Platelet count increased to normal levels after treatment.
FRONTIERS IN PEDIATRICS
(2023)
Article
Virology
Danielle A. Rankin, Ahmad Yanis, Rana Talj, Harrison L. Howe, Sean M. Bloos, Kailee N. Fernandez, Justin Z. Amarin, Mercedes Bruce, Seifein Salib, Samarian Hargrave, James D. Chappell, Andrew J. Spieker, Natasha B. Halasa, Leigh M. Howard
Summary: Compared to adults, children infected with SARS-CoV-2 are less likely to develop severe symptoms, with a higher prevalence of asymptomatic cases and shorter illness duration. The differences in clinical presentation across age groups may inform targeted testing, screening, and management strategies.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Review
Hematology
Yumei Liu, Zonghong Shao, Huaquan Wang
Summary: Vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but severe complication after adenoviral vector vaccines, has attracted global attention. Its pathogenesis is similar to heparin-induced thrombocytopenia (HIT), and it has a high mortality rate.
THROMBOSIS RESEARCH
(2022)